Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro.
Glatiramer acetate (GA) prevents TNF-α-induced monocyte adhesion to primary endothelial cells through interfering with the NF-κB pathway.
Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
Neuronal expression of pathological tau accelerates oligodendrocyte progenitor cell differentiation.
Biologics-induced autoimmune diseases.
NF-κB transcriptional activation by TNFα requires phospholipase C, extracellular signal-regulated kinase 2 and poly(ADP-ribose) polymerase-1.
IL-17 and GM-CSF Expression Are Antagonistically Regulated by Human T Helper Cells.
Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients.
Biogen Idec receives notification of PDUFA date extension for PLEGRIDY™ (peginterferon beta-1a)
CCR2 defines in vivo development and homing of IL-23-driven GM-CSF-producing Th17 cells.
Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis.
Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
Molecular characterization of a peripheral receptor for cannabinoids.
Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development.
PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients
β-Amyloid: Enemy or Remedy?
Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?
Study of teriflunomide in reducing the frequency of relapses and accumulation of disability in patients with multiple sclerosis (TEMSO)
Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
Combination therapy of interferon Beta-1b and tacrolimus: a pilot safety study.
Insight into the mechanism of laquinimod action.
Masitinib is being investigated in the treatment of amyotrophic lateral sclerosis (ALS)
Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid communication.

Pages